| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Yale University |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000318 |
Purpose
The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders Substance-Related Disorders |
Drug: Buprenorphine |
Phase II |
| Drug Information available for: | Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot |
| Estimated Enrollment: | 21 |
| Study Start Date: | December 1995 |
| Arms | Assigned Interventions |
|
1: Experimental
Maintenance treatment with daily medication
|
Drug: Buprenorphine
|
|
2: Experimental
Maintenance treatment with thrice-weekly medication
|
Drug: Buprenorphine
|
Eligibility
| Ages Eligible for Study: | 21 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Connecticut | |||||
| APT Residential Services Division | |||||
| New Haven, Connecticut, United States, 06519 | |||||
| National Institute on Drug Abuse (NIDA) |
| Yale University |
| Principal Investigator: | Richard Schottenfeld, M.D. | Yale University |
More Information
| Responsible Party: | Yale University School of Medicine ( Richard S. Schottenfeld, MD ) |
| Study ID Numbers: | NIDA-09803-1, R01-09803-1 |
| First Received: | September 20, 1999 |
| Last Updated: | October 27, 2008 |
| ClinicalTrials.gov Identifier: | NCT00000318 |
| Health Authority: | United States: Federal Government |
|
|
|
|
